Initiates Coverage on Akari Therapeutics (NASDAQ:AKTX)

Research analysts at assumed coverage on shares of Akari Therapeutics (NASDAQ:AKTXGet Rating) in a research report issued to clients and investors on Wednesday. The brokerage set a “sell” rating on the biopharmaceutical company’s stock.

AKTX opened at $0.99 on Wednesday. Akari Therapeutics has a 1-year low of $0.95 and a 1-year high of $1.88. The company has a market capitalization of $58.46 million, a PE ratio of -2.37 and a beta of 1.25. The firm’s 50 day simple moving average is $1.12 and its two-hundred day simple moving average is $1.27.

Akari Therapeutics (NASDAQ:AKTXGet Rating) last released its quarterly earnings results on Monday, May 16th. The biopharmaceutical company reported ($0.12) earnings per share for the quarter.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Hikari Power Ltd raised its position in Akari Therapeutics by 45.7% in the first quarter. Hikari Power Ltd now owns 130,821 shares of the biopharmaceutical company’s stock worth $157,000 after acquiring an additional 41,006 shares during the period. Omnia Family Wealth LLC raised its position in Akari Therapeutics by 13.7% in the first quarter. Omnia Family Wealth LLC now owns 758,144 shares of the biopharmaceutical company’s stock worth $910,000 after acquiring an additional 91,059 shares during the period. Finally, Wsfs Capital Management LLC bought a new stake in shares of Akari Therapeutics during the 4th quarter valued at $150,000. Institutional investors and hedge funds own 2.50% of the company’s stock.

About Akari Therapeutics (Get Rating)

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid.

Featured Articles

Receive News & Ratings for Akari Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akari Therapeutics and related companies with's FREE daily email newsletter.